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AbstrAct
TMPRSS2-ERG has been proposed to be a prognostic marker for prostate 
cancer. The aim of this study was to identify changes in metabolism, genes and 
biochemical recurrence related to TMPRSS2-ERG by using an integrated approach, 
combining metabolomics, transcriptomics, histopathology and clinical data in a cohort 
of 129 human prostate samples (41 patients). Metabolic analyses revealed lower 
concentrations of citrate and spermine comparing ERGhigh to ERGlow samples, suggesting 
an increased cancer aggressiveness of ERGhigh compared to ERGlow. These results 
could be validated in a separate cohort, consisting of 40 samples (40 patients), and 
magnetic resonance spectroscopy imaging (MRSI) indicated an in vivo translational 
potential. Alterations of gene expression levels associated with key enzymes in 
the metabolism of citrate and polyamines were in consistence with the metabolic 
results. Furthermore, the metabolic alterations between ERGhigh and ERGlow were more 
pronounced in low Gleason samples than in high Gleason samples, suggesting it as a 
potential tool for risk stratification. However, no significant difference in biochemical 
recurrence was detected, although a trend towards significance was detected for low 
Gleason samples. Using an integrated approach, this study suggests TMPRSS2-ERG 
as a potential risk stratification tool for inclusion of active surveillance patients. 
IntroductIon 
The genetic fusion between the erythroblast 
transformation-specific (ETS) transcriptional factor 
ETS-related gene (ERG) and the androgen-responsive 
promotor transmembrane protease, serine 2 (TMPRSS2) 
[1] is suggested to be a major mechanism driving prostate 
carcinogenesis. The TMPRSS2-ERG gene fusion is the 
most common gene rearrangement in prostate cancer [2], 
with a reported prevalence of 15-78% [3]. Presence of 
the gene fusion is the main reason for overexpression 
of ERG which is further associated with epithelial-
to-mesenchymal potential, cell invasion and cell 
proliferation [4].
From the initial discovery in 2005 [5], the 
TMPRSS2- ERG gene fusion has been linked to clinical 
outcome parameters such as early onset of prostate 
cancer [6], negative outcome in watchful waiting patients 
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[7–9] and a higher risk of disease progression in active 
surveillance patients [10]. However, considering the 
prognostic value of TMPRSS2-ERG in prostatectomy 
patients, most studies find no association to outcome 
after surgery [6, 11–13]. In a meta-analysis of 5,074 
prostatectomy specimens, there were no associations 
between the presence of TMPRSS2-ERG and biochemical 
recurrence or lethal disease [14]. Although the clinical 
significance of TMPRSS2-ERG is yet to be proven, 
presence of the fusion gene is a key genomic event 
specific for prostate cancer that may be of importance 
for risk assessment or treatment stratification of prostate 
cancer patients.   
Metabolic markers may be indicative of aggressive 
disease and provide diagnostic and therapeutic 
information for improved characterization and 
stratification of prostate cancer patients. Lower levels 
of citrate and spermine have previously been linked to 
higher Gleason grade and more aggressive prostate cancer 
[15]. Citrate and spermine, including choline and creatine 
are metabolites detectable by in vivo patient magnetic 
resonance spectroscopy imaging (MRSI), which imply a 
potential for transferring biomarkers to a clinical setting 
[16]. A recent study revealed ERG-specific metabolic 
alterations, particularly connected to fatty acid oxidation 
[17] and an earlier study found increased glucose uptake 
to be related to the metabolic sensor neuropeptide gamma 
(NPY) in ERG rearrangement positive prostate cancer 
[18]. Apart from these two studies, the relationship 
between cancer metabolism and TMPRSS2-ERG remains 
unexplored.
The integration of transcriptomic data with 
metabolomics and histopathology is a promising tool 
for gaining important molecular information, in order 
to understand states and pathways of disease. In this 
study, we used prostatectomy tissue samples obtained 
through a standardized harvesting protocol [19] where 
metabolic and gene expression data are collected after 
histopathology evaluation [20] in order to integrate data 
from transcriptomics, metabolomics and histopathology. 
Prostate tissue samples were analyzed by HR-MAS 
(high resolution magic angle spinning) MRS (magnetic 
resonance spectroscopy), followed by detection of 
the fusion gene using gene expression microarray 
measurements for the main cohort, and fluorescence 
in situ hybridization (FISH) for an independent validation 
cohort. HR-MAS is a non-destructive method, which 
permits gene expression analysis and histology to be 
performed on the exact same tissue sample, providing 
an excellent basis for correlating metabolic findings with 
concordant alterations in the transcriptome. The main 
objective of this study was to combine these techniques to 
investigate presence of the TMPRSS2-ERG gene fusion 
in two cohorts of human prostate cancer tissue and to 
identify its association to metabolism and biochemical 
recurrence.
results And dIscussIon
The presence of TMPRSS2-ERG or expressing 
high ERG levels was in our prostate cancer patient 
cohorts associated with metabolic alterations and 
concordant changes of gene expression levels related to 
key metabolic genes. In two independent patient cohorts, 
we observed a decrease in concentrations of citrate 
and spermine in fusion positive and ERGhigh patients, 
indicating increased aggressiveness according to previous 
findings on prostate cancer metabolism [15]. In addition, 
this relationship was significant within low Gleason 
samples which propose an early patient stratification 
possibility based on the fusion status and metabolic 
biomarkers. 
Presence of tMPrss2-erG/high erG status
A 2 mm transversal prostate tissue slice was 
collected from 41 patients and from each slice several 
samples (median: 3, range: 1 to 6 per slice, depending on 
tumor size) were collected from cancerous and adjacent 
benign areas, in total 95 cancer and 34 benign samples, 
and termed the main cohort. Among the cancer samples, 
34 of 95 (35.8%) were classified as ERGhigh, and were 
expected to possess the TMPRSS2-ERG fusion gene, 
while 30 (31.6%) and 31 (32.6%) were classified as 
ERGlow and ERGintermediate, respectively. In addition, 34 
(26.4%) of the 129 samples in the cohort were classified 
as benign samples. The proportions harboring the fusion 
gene are in the lower range of the reported prevalence of 
15-78% [3].
Generally, samples obtained from the same 
prostate, were all placed in the same ERG group or the 
adjacent ERG group. However, out of the 41 patients, 
6 (14.6%) patients had samples belonging to all three 
ERG groups (Supplementary Table S1), which is in 
consistence with previously reports of ERG interfocal 
heterogeneity [21, 22]. Three patients had no cancer 
samples, leaving 38 patients as the main focus of this 
study. In order to validate our results, a second cohort 
of 90 prostate cancer patients was included, consisting 
of one needle biopsy sample per patient obtained after 
radical prostatectomy. Only 40 of the needle biopsies 
contained cancer and were included in the present study. 
In the validation cohort, 7 out of 40 patients, (17.5%) 
were fusion positive, while 33 out of 40 (82.5%) were 
fusion negative. The lower prevalence of TMPRSS2-
ERG in the validation cohort may be due to a lower 
amount of tumor in the samples (median cancer content 
40% and 70% in the validation and main cohort, 
respectively) and sampling only one sample per patient 
may fail to detect presence of TMPRSS2-ERG present in 
other parts of the prostate. Sample characteristics of both 
cohorts are presented in Table 1. 
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Metabolic alterations associated with tMPrss2-
erG/high erG status
Unsupervised multivariate analysis of the metabolic 
profiles of the main cohort revealed a trend of clustering 
with respect to the three different ERG groups and 
the benign samples (Figure 1A). Significant trends 
across increasing ERG groups (cancer samples) were 
detected for the levels of citrate, spermine, putrescine, 
ethanolamine, glucose, glycine, phosphocholine and 
phosphoethanolamine (Figure 1B and Table 2). In normal 
prostate cells citrate is accumulated, while in prostate 
cancer, citrate is decreased or depleted [23]. Additionally, 
the normal  prostate cells  have  one  of  the  highest 
concentrations  of  polyamines  in  the  body [24], and 
the polyamines are important  for  a variety  of  functions 
within  the  cell  such as e.g. apoptosis, cell proliferation 
and differentiation [25, 26]. Decreasing levels of citrate, 
spermine and putrescine with increasing ERG status, 
suggested increased aggressiveness [15] of higher ERG 
status groups compared to lower ERG status groups. 
The increased levels of ethanolamine, phosphocholine 
and phosphoethanolamine further suggest an increased 
aggressiveness of the higher ERG status, as increased 
concentrations of choline-associated metabolites have 
been reported in prostate cancer, and are important 
in proliferation as structural components of cellular 
membranes [27, 28]. Glycine may also be important 
considering previous findings in breast cancer, suggesting 
it to be a marker of lower survival rates [29]. 
Comparable results were found building a partial 
least squares discriminant analysis (PLS-DA) model based 
on the metabolic profiles where ERGhigh was separated 
from ERGlow with an accuracy of 77% (sensitivity: 79%, 
specificity: 74%), p < 0.001 (Figure 1C). This proves that 
the metabolic profiles of samples which are expected to 
possess the fusion gene are well separated from those most 
likely not to harbor the gene rearrangement. Further, the 
loading plot for the latent variable 1 (LV1) (Figure 1D), 
explaining which metabolites that are important for the 
separation along LV1, showed decreased levels of citrate 
and polyamine levels in ERGhigh compared to ERGlow, 
while levels of choline-containing compounds were 
higher, supporting the hypothesis of a more aggressive 
phenotype of fusion positive prostate cancers.  
Among the 23 quantified metabolites in the main 
cohort, the concentrations of citrate, spermine, putrescine 
and glucose were significantly decreased in ERGhigh samples 
compared to ERGlow, while the concentrations of glycine were 
significantly increased (Supplementary Table S2). However, 
after multiple testing corrections, only citrate and spermine 
were significant (Figure 2A and 2B, Table 2). In addition, 
table 1: clinical characteristics for samples in the main- and validation cohort
Main cohort Validation cohort




Prevalence 30 31 34 33 7
Gleason score of tissue samples
0 0 0 0 0 0
6 7 8 9 5 1
3 + 4 5 8 8 11 3
4 + 3 4 7 9 9 0
8 8 2 5 3 2
9 6 6 3 2 1
10 0 0 0 2 0
Not evaluated - - - 1 -
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our study revealed similar metabolic levels between ERGlow 
and benign samples (Supplementary Table S3), possibly 
confounded by effects of tissue heterogeneity [30], especially 
differences in stromal content between cancer and benign 
samples. Similar metabolic levels of citrate and spermine 
have previously been found comparing low Gleason grade 
and benign samples [15]. Despite the low prevalence of the 
fusion gene in the validation cohort, significantly decreased 
concentrations of citrate and spermine were detected in 
fusion positive samples. However, these differences were not 
Figure 1: Multivariate analysis of spectral data and absolute quantification reveals metabolic differences between ERG 
groups. (A) Principal component analysis (PCA) reveals a trend in the distribution of the metabolic clusters of metabolic profile from benign 
samples (purple) across ERGlow (blue) and ERGintermediate (green) to ERGhigh (yellow). (b) Absolute quantification of 23 metabolites 
showed significant trend across cancer samples, from ERGlow, (blue) through ERGintermediate (green) to ERGhigh (yellow) for eight of 
the metabolites. Increasing trends were found for glycine, phosphocholine, phosphoethanolamine, and ethanolamine. Decreasing trends 
were found for citrate, spermine, putrescine and glucose. Benign (purple) samples are shown for comparisons. (c) A partial least squares 
discriminant analysis (PLS-DA) model was able to separate ERGhigh (yellow) and ERGlow (blue) with a accuracy of 77 %, p < 0.001. 
(d) Loadings plot of latent variable 1 (LV1) indicate lower levels of citrate and the polyamines and higher levels of choline-containing 
metabolites comparing ERGhigh to ERGlow. The loadings are colored according to the variable importance in the projection (VIP) scores.
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significant after corrections for multiple testing, possibly due 
to the relatively small patient cohort, variations in the amount 
of cancer tissue between samples and the low number of 
fusion positive samples in this cohort (Figure 2C and 2D, 
Supplementary Table S4). A recent study [17] supports our 
metabolic findings by presenting significantly increased 
levels of glycerophosphoethanolamine, glycine, isoleucine, 
leucine and glutamate between ERG positive and ERG 
negative patients, and significantly decreased levels of myo-
inositol, creatine, citrate, glucose, spermine and putrescine. 
However, we were not able to reveal any metabolic changes 
related to glycerophosphoethanolamine, isoleucine, leucine, 
glutamate and myo-inositol suggested by Meller et al. [17].  
targeted analyses of key metabolic pathways 
Due to the observed citrate and spermine changes, 
we performed targeted analyses of genes related to the 
polyamine pathway and citrate. We also investigated 
metabolic pathways connected to glycine and glucose 
metabolism, as TMPRSS2-ERG has been suggested to be 
linked to increased glucose uptake [17, 18]. 
the polyamine pathway
Expression of polyamine pathway genes were found 
to be increased in ERGhigh samples compared to ERGlow, 
where spermidine synthase (SRM) and spermidine N(1)-
acetyltransferase (SAT1) displayed the highest significance 
(Figure 3A and Supplementary Table S5). Especially, the 
strong upregulation of SAT1 leads to a rapid depletion 
of cellular spermidine and spermine [31], which is in 
agreement with the low concentrations of spermine 
observed in ERGhigh compared to ERGlow. In addition, 
overexpression of SRM without concordant upregulation 
of ornithine decarboxylase (ODC1) will lead to reduced 
levels of putrescine which was observed in the present 
study. ODC1 overexpression is reported frequently among 
prostate cancer patients [32, 33], where it mediates the 
conversion of ornithine to putrescine which is the rate-
limiting enzyme of the polyamine pathway. However, 
this does not seem to be the main mode of regulation 
in ERGhigh versus ERGlow samples in our cohort, where 
changes in SAT1 and SRM seem to be the main drivers of 
altered polyamine metabolism.  
citrate and fatty acid synthesis
In the present study, we found that a significantly 
decreased expression of ACO2 in the TCA cycle (Figure 3B 
and Supplementary Table S5) is linked to a phenotype 
characterized by low levels of citrate in ERGhigh tissue 
samples. Franklin and Costello [34] suggested that 
normal prostate epithelial cells are citrate-producing, but 
become citrate-oxidizing following transformation to 
malignant cells, and that ACO2 is the key enzyme for this 
transformation. Decreased expression of ACO2 have been 
linked to increased citrate secretion [35], causing higher 
levels of citrate which can be redirected to the cytosol, 
contributing to restore acetyl-CoA and oxaloacetate pools. 
Our results indicate that citrate is shunted out to the cytosol 
where it may be used for de novo synthesis of fatty acids to 
meet the high demands for building blocks for biosynthesis 
in cancer, as we observed an increased expression of the 
Table 2: Differences in levels of quantified metabolites in the main cohort comparing ERGhigh 



























Citrate 9.44 (5.56 to 14.68) 6.74 (3.94 to 10.34) 3.91 (2.59 to 7.20) < 0.001 < 0.001 < 0.001
Ethm 0 (0 to 0) 0 (0 to 0.15) 0.01 (0 to 0.31) 0.490 0.663 0.043
Glucose 0.15 (0.00 to 0.63) 0.00 (0.00 to 0.43) 0.00 (0.00 to 0.07) 0.008 0.061 0.007
Glycine 1.99 (1.68 to 2.78) 2.51 (1.98 to 3.18) 2.90 (1.93 to 3.65) 0.023 0.115 0.008
PCh 0.61 (0.33 to 0.91) 0.63 (0.43 to 1.17) 0.96 (0.64 to 1.36) 0.067 0.248 0.005
PE 2.33 (1.46 to 3.51) 2.57 (1.67 to 4.14) 2.86 (2.33 to 3.79) 0.087 0.248 0.032
Putrescine 0.12 (0 to 0.67) 0.06 (0 to 0.30) 0 (0 to 0.10) 0.025 0.115 0.003
Spermine 2.10 (1.20 to 3.19) 1.23 (0.79 to 2.02) 0.89 (0.45 to 1.40) < 0.001 < 0.001 < 0.001
Ethm: Ethanolamine, PCh: Phosphocholine, PE: Phosphoethanolamine, IQR: Interquartile range. Adjusted p-values are 
adjusted using Benjamini-Hochberg correction for multiple testing.
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Figure 2: box-plots for citrate and spermine comparing erGhigh and erGlow samples in the main cohort (ex vivo) 
and fusion positive and fusion negative patients in the validation cohort. (A) Decreased levels of citrate were found comparing 
ERGhigh to ERGlow samples in the main cohort, p < 0.001, (b) Decreased levels of spermine were found comparing ERGhigh to ERGlow 
samples in the main cohort, p < 0.001, (c) Decreased levels of citrate were found comparing fusion positive to fusion negative patients in 
the validation cohort, p = 0.013, (d) Decreased levels of spermine were found comparing fusion positive to fusion negative patients in the 
validation cohort, p = 0.021.
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key lipogenic enzymes acetyl-CoA carboxylase alpha 
(ACACA) and fatty acid synthase (FASN) in ERGhigh tissue 
samples. Additionally, a higher expression of long-chain 
acyl-CoA synthetase3 (ASCL3) was detected, which is 
previously suggested to cause lipid accumulation [36]. 
High expression of FASN, have been found increased in 
several types of cancers, including prostate cancer and is 
strongly correlated with malignant transformation and 
poor prognosis [37, 38]. Increased fatty acid synthesis is 
suggested to be a key feature of prostate cancer suggesting 
aggressiveness of disease [38], and the increased lipogenic 
profile of ERGhigh samples supports the hypothesis of an 
increased aggressiveness with presence of TMPRSS2-ERG.
Glucose, glycine and pentose phosphate pathway
A significant reduction of glucose was found prior 
to correction for multiple testing, comparing ERGhigh 
with ERGlow. We detected a differential expression of 
NPY, in line with results from a previous study [18], 
comparing ERGhigh and ERGlow samples, where lower 
levels of glucose were connected to a phenotype with 
a higher expression of NPY. Our results indicate that 
ERGhigh samples have lower glucose levels or are rapidly 
consuming glucose and thus lowering the detectable 
glucose levels. Moreover, there was not an increased 
concentration of lactate in ERGhigh compared to ERGlow, 
and both increased and decreased expression of key 
enzymes within glycolysis and the TCA were detected 
(Figure 3B and Supplementary Table S5). However, a 
highly significant increased expression of oxoglutarate 
dehydrogenase-like (OGDHL), a key control point in 
the TCA, was found in ERGhigh compared to ERGlow. 
Interestingly, the increased expression of pyruvate 
kinase (PKM2) may slow glycolysis and redirect 
carbohydrate intermediates to e.g. the pentose phosphate 
pathway (PPP). This is supported by overexpression 
of key enzymes both in the oxidative and the 
reductive part of the PPP, specifically the expression 
of 6-phosphogluconolactonase (PGLS), transketolase 
(TKT), and ribokinase (RBKS) (Supplementary Table S5). 
Collectively, these results suggest that glucose may be 
shunted into the PPP among ERGhigh samples. The PPP 
provides nucleotide precursors and helps regenerate 
NADPH which is important for maintaining the redox 
state and for supporting the synthesis of fatty acids for 
cancer cells [39]. 
When investigating the most central genes 
associated with the metabolism of glycine we did not 
find any possible explanation for the increased levels 
of glycine among ERGhigh compared to ERGlow samples 
(Supplementary Table S5). 
Risk stratification based on the presence of 
tMPrss2-erG 
Risk stratification for choice of treatment in 
low grade prostate cancer is currently a challenge. 
We therefore investigated the possibility to stratify 
patients according to the presence of fusion/ERG 
Figure 3: Schematic representation of pathways and gene expression levels of associated key enzymes altered due to presence of the 
fusion gene (A) the polyamine pathway, gene/protein names: ODC1: ornithine decarboxylase 1, SRM: spermidine synthase, SMS: spermine 
synthase, SAT1: spermidine/spermine N1-acetyltransferase 1 (blue = down-regulation, red = up-regulation) and (b) TCA cycle, fatty acid 
synthesis and pentose phosphate pathway. ACO1/2: aconitase 1/2, ACACA: acetyl-CoA carboxylase alpha, FASN: fatty acid synthase, 
HK: hexokinase, PKM2: pyruvate kinase, PGLS: 6-phosphogluconolactonase, RBKS: ribokinase, and TKT: transketolase (blue = down-
regulation, red = up-regulation).
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status within low Gleason samples (Gleason score 
≤ 3 + 4). We detected pronounced differences both 
in metabolism and gene expression levels between 
ERGhigh and ERGlow, restricted to low Gleason samples 
(Supplementary Table S8). A significant decrease in 
the concentrations of citrate, spermine, putrescine and 
glycerophosphoethanolamine were detected in ERGhigh 
samples compared to ERGlow samples, and a significant 
increase were found in glutamine and glycine after 
multiple testing corrections (Supplementary Table S8). 
However, restricting our analyses to high Gleason 
samples (Gleason score ≥ 4 + 3), only significantly 
decreased concentrations of citrate and spermine were 
observed comparing ERGhigh and ERGlow (Supplementary 
Table S9). Expression levels of key enzymes in the 
metabolism of the polyamines, glucose and fatty acid 
displayed higher significance levels when restricting 
the analyses to low Gleason samples compared to high 
Gleason samples (Supplementary Table S6 and S7). 
As both the metabolic and the gene expression 
levels were more pronounced in the low Gleason group, 
presence of the fusion gene may serve as a tool for 
risk- or treatment stratification of low Gleason patients. 
In high Gleason samples, we generally observed less 
significant metabolic and transcriptomic alterations 
due to ERG status. High Gleason score has been linked 
to genomic instability and multiple genetic alterations 
[40, 41]. As the high Gleason samples are heterogeneous, 
the transcriptomic- and metabolic differences between 
ERGhigh and ERGlow may possibly be masked by the 
effect of other genetic alterations present among these 
samples. 
To increase the understanding of metabolism 
associated with the presence of the fusion gene, INMEX 
and ssGSEA analyses were performed, and indicated 
several metabolic pathway differences between ERGhigh 
and ERGlow (Figure 4A) including glutathione (including 
polyamines), glycolysis, and additionally purine 
and pyrimidine, which are important precursors for 
nucleotides (Supplementary Table S10). In concordance 
with our findings in metabolic concentrations, 
both INMEX and GSEA showed more significant 
differences when the analyses were restricted to low 
Gleason samples (Figure 4B) than to high Gleason 
samples (Figure 4C). These results are presented in 
Supplementary Tables S11–S18. 
In conclusion, metabolic alterations in the presence 
of the fusion gene are more pronounced in the low grade 
compared to aggressive cancer, and may be suggested as 
a possible risk stratification tool for low Gleason prostate 
cancer patients. Metabolism suggests a more aggressive 
phenotype connected to presence of the fusion gene. 
However, further studies on prognostics and validation 
are needed. Due to the small number of samples in the 
validation cohort, metabolic differences between low- and 
high Gleason samples could not be validated by this cohort.
biochemical recurrence and erG status
Prognostics and biochemical recurrence connected 
to presence of the fusion gene have previously shown 
varying results [14]. At a median follow-up of 6.5 years 
in our study (range 1.8 to 8.3 years), 10 (33.3%) of 
the 30 patients with follow-up data had experienced 
biochemical recurrence (prostate-specific antigen 
(PSA) ≥ 0.2 ng/ml). No significant difference was 
observed in biochemical recurrence between ERGhigh 
and ERGlow patients in the main cohort (Figure 4D–4F), 
which is in agreement with other studies on radical 
prostatectomy cohorts [6, 11–14]. However, there was 
a trend towards significance when restricting to the low 
Gleason patients, p = 0.205 (Figure 4E). Due to the low 
number of included patients, the current study may not 
have the sufficient statistical power to reveal significant 
differences in rate of biochemical recurrence between 
ERGhigh and ERGlow.
translational potential by in vivo patient 
magnetic resonance spectroscopy imaging
The potential of transferring biomarkers and 
knowledge to 3T and 7T in vivo patient MRSI [16], 
makes HR-MAS MRS on prostate tissue samples 
attractive for basic research. A subset of the patients 
in the main cohort (9 patients, 21 samples) had data 
from in vivo MRSI acquired prior to surgery. The 
in vivo spectroscopy voxels were spatially matched to the 
HRMAS tissue samples [16]. The in vivo citrate/creatine 
ratio from spatially matched voxels was decreased with 
borderline significance in ERGhigh compared to ERGlow, 
p = 0.083 (Figure 5A), while choline/creatine and 
spermine/creatine ratios were not significant, p = 0.667 
and p = 0.158, respectively (Figure 5B). However, in the 
low Gleason group (5 patients, 11 samples), the citrate/
creatine ratio was significantly decreased, p < 0.001 
(Figure 5C) and in addition, the levels of choline/creatine 
ratio was significantly increased (p = 0.041), while 
the spermine/creatine ratio was borderline decreased 
(p = 0.094) in ERGhigh compared to ERGlow (Figure 5D). 
Within high Gleason samples (4 patients, 10 samples), 
only a decreased choline/creatine ratio was significantly 
detected (p = 0.018), comparing ERGhigh to ERGlow. 
Alterations in MRSI in vivo measured citrate, choline and 
spermine levels may offer a possibility for stratification 
of low risk prostate cancer patients without the need 
of biopsies, and a possibility to enroll patients into 




This study presents a distinct metabolic profile 
with concordant alterations of gene expression levels 
of key metabolic enzymes in prostate tissue samples 
with the presence of TMPRSS2-ERG. The metabolic 
profile was especially connected to the metabolism 
of polyamines and citrate, but also glycolysis and 
fatty acid metabolism. Our results indicate that 
TMPRSS2-ERG differentiates towards a phenotype 
that is associated with characteristics of an aggressive 
phenotype of prostate cancer. Additionally, the observed 
metabolic alterations can be translated to in vivo patient 
MRSI.
Figure 4: single sample GseA (ssGseA) show alterations of several key metabolic pathways and biochemical 
recurrence for erGhigh and erGlow and Kaplan-Maier plots for biochemical recurrence. ssGSEA results of key 
metabolic pathways for the main cohort (A) the low Gleason samples (b) and the low Gleason samples within the main cohort (c) where 
red indicates up-regulation of the given gene set and blue down-regulation of a given gene set. Pathways with significantly different (p < 
0.05) ssGSEA-values comparing ERGhigh and ERGlow while adjusting for multiple samples per patient, are indicated in bold. Kaplan-
Maier plots for ERGhigh and ERGlow in the main cohort (d), low Gleason patients (e) and high Gleason patients (F).
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Figure 5: box-plots for citrate and spermine comparing erGhigh and erGlow samples in the main cohort (in vivo). 
(A) No significant difference in levels of citrate/creatine in the main cohort (in vivo MRSI) between ERGhigh and ERGlow, p = 0.083, 
(b) Decreased levels of citrate/creatine were found comparing ERGhigh to ERGlow in the main cohort (in vivo MRSI), restricting to low 
Gleason samples, p < 0.001, (c) No significant difference in levels of spermine/creatine between ERGhigh and ERGlow in the main cohort 
(in vivo MRSI), p = 0.158, (d) No significant difference in levels of spermine/creatine were found comparing ERGhigh and ERGlow in the 
main cohort (in vivo MRSI), restricting to low Gleason samples, p = 0.094.
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MAterIAls And Methods 
samples and patient cohorts
In the main cohort, a 2 mm transversal prostate 
tissue slice was collected from 48 prostate cancer 
patients after radical prostatectomy at St.Olavs Hospital, 
Trondheim, between 2007 and February 2010, with no 
previous treatment for prostate cancer, using a highly 
standardized harvesting method thoroughly described by 
Bertilsson et al. [15, 19]. From each tissue slice, several 
samples (average: 6, range: 4 to 11 per slice, depending on 
tumor size) were collected from cancerous and adjacent 
benign areas. In total 362 samples were extracted for 
RNA and acceptable RNA integrity number (RIN) scores 
were obtained from 354 samples. Samples with a high 
Gleason score, large extent of cancer and high quality 
RNA were prioritized. Seven patients were excluded either 
due to lack of cancer in the extracted samples (2 slices) 
or lack of quality of the samples in the microarray 
analyses (5 slices), and 4 samples were excluded due to 
low HR- MAS spectral quality. In total 95 cancer and 34 
benign samples from 41 patients (median: 3, range: 1 to 6 
per slice) were collected. 
For validation of the results, a second cohort of 90 
prostate cancer patients was included, consisting of one 
needle biopsy sample per patient obtained after radical 
prostatectomy. The samples were selected from a large 
biobank (~1000 patients, ~2000 samples) collected 
from prostate cancer patients after radical prostatectomy 
at St.Olavs Hospital, Trondheim, between 2007 and 
February 2010. The samples were selected from patients 
with highest tumor volume in order to collect tissue with 
high cancer content. The patients had not received any 
treatment for prostate cancer prior to sampling. Only 40 of 
the needle biopsies contained cancer and were included in 
the present study. The two cohorts were independent, i.e. 
no patient belonged to both cohorts. Sample characteristics 
for the main cohort and the validation cohort are given 
in Table 1. Both cohorts are approved by the Regional 
Committee of Medical and Health Research Ethics (REC), 
Central Norway, and all patients gave written, informed 
consent.
hr-MAs Mrs
1H HR-MAS MRS analysis was performed as 
previously described [15, 19]. Acquired spectral data were 
exponential Fourier transformed (line broadening 0.3 Hz), 
baseline- and phase-corrected using Topspin 3.2 (Bruker 
Biospin, Germany). Samples in the validation cohort were 
of equivalent weight (mean weight: 12.3 mg, range 6.7 to 
21.9 mg) to samples in the main cohort (mean weight: 12.7 
mg, range: 3.0 to 21.9 mg). Samples were hematoxylin- 
and eosin stained (HE, main cohort) or hematoxylin-eosin-
saffron stained (HES, validation cohort) due to different 
routines in staining protocols at different times. HE/HES 
stained sections were used for histopathological evaluation 
of Gleason grading and assessment of cancer-, benign 
epithelial-, and stromal content. Two pathologists (TV 
and ER) evaluated the sections from the main cohort and 
an interrater agreement (κ) of 0.66, indicating substantial 
agreement, was found for distinguishing the samples 
into benign, low Gleason (Gleason score ≤ 3 + 4) and 
high Gleason (Gleason score ≥ 4 + 3). The first reading 
(TV) was used for grading in this study due to a slight 
degradation of the cryosections from the initial reading to 
the second reading. The validation cohort sections were 
evaluated by one pathologist (TV). 
Definition of ERG groups and combining 
transcriptomics and metabolomics data
Gene expression profiles from the main cohort 
were obtained as previously described by Bertilsson 
et al. [19, 20]. The microarray data has previously been 
published in Array Expression with access number: 
E-MTAB-1041. The gene expression data were log2 
transformed and quantile normalized [20]. Gene Set 
Enrichment Analysis (GSEA) scores were calculated 
for detection of specific enrichment of the ERG-fusion 
gene set based on prostate cancer related gene sets [42] 
as previously described by Rye et al. [43]. GSEA focuses 
on gene sets, i.e. groups of genes that share common 
biological function, chromosomal location, or regulation 
and in order to detect pathway changes more sensitively 
[44]. Based on the overall ERG GSEA score the samples 
were classified as ERGhigh if the score were increased 
two-fold compared to the mean ERG GSEA of the cancer 
samples. The rest of the cancer samples were equally 
divided into groups of ERGlow and ERGintermediate. The 
ERGhigh samples were defined as possessing the highest 
probability for being fusion positive, while the ERGlow 
samples were defined as having the lowest probability for 
being fusion positive. Due to uncertainties of the fusion 
status of the ERGintermediate group, most of the differential 
analyses of metabolite and gene expression levels were 
performed comparing the ERGhigh and ERGlow groups. 
Classification of samples per patient to the individual ERG 
groups is presented in Supplementary Table S1.
To link transcriptomic and metabolomics data 
connected to ERG status, we used two approaches; 1) 
integrative meta-analysis of expression data (INMEX) 
where lists of genes and metabolites (individually 
analyzed) are combined and significant genes and 
metabolites are mapped to Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways [45], and where 
enrichment and topology analysis identify important 
pathways [46], 2) single sample GSEA (ssGSEA) [44] 
calculates separate enrichment scores for each pairing 
of a sample and gene set, which represents the degree 
of up- or down-regulation of a gene [47]. Enrichment of 
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KEGG  gene set collections in the Molecular Signatures 
Database (Broad Institute, version 5.0) were performed 
using the GSEA software (Broad Institute, version 
2.0.14) [44, 48]. ssGSEA analyses were performed using 
ssGSEAprojection [47], and results from the 38 most 
relevant metabolic pathways were visualized using 
HeatMapViewer (version 13), using GenePattern (version 
3.9.4) [49].
Fluorescence in situ hybridization
The TMPRSS2-ERG status of samples in the 
validation cohort was determined by using a break-
apart assay with a triple-labeled color commercial probe 
(Kreatech Diagnostics, The Netherlands). The probe 
detects the deletion between TMPRSS2 and ERG at 21q22. 
The FISH assay was carried out on 4 µm formalin-fixed, 
paraffin-embedded tissue sections after deparaffinization 
which were then pretreated using a commercial tissue 
section kit for paraffin-embedded tissue (Histology FISH 
Accessory Kit, Dako). The probe mix was applied and 
denatured at 80°C for 5 minutes before hybridization 
at 37°C overnight using a Dako hybridizer. The slides 
were counterstained with DAPI (4’,6-diamidino-2-
phenylindole) from the Histology FISH Accessory kit. 
Results were visualized using a 100x oil immersion 
objective on a Nikon Eclipse 90i fluorescent microscope 
(Nikon Corp., Japan) equipped with appropriate filters. For 
each sample, 25 non-overlapping nuclei in cancer areas 
were evaluated for deletion of the TMPRSS2 (21q22) 
gene region associated with TMPRSS2-ERG. In order to 
compensate for nuclear truncation, the cut-off level for an 
informative result was defined as loss of the TMPRSS2 
(21q22) gene region at least 80% of tumor cell nuclei. 
luminal space measurements
Cryosections from the main cohort and the paraffin-
embedded sections from the validation cohort were 
digitalized with 40x magnification and the luminal spaces 
were identified using a color-based segmentation (positive 
pixel count algorithm in ImageScope v8.0, Aperio 
Technologies) as described by Langer et al. [50]. 
Quantification of metabolites
Individual metabolites in the HR-MAS spectra 
were quantified using LCModel [51] based on a basis 
set containing 23 metabolites generated using NMRSIM 
(Bruker BioSpin, Germany) as previously described by 
Giskeødegård et al. [15]. Similarly, a separate basis set of 
25 metabolites was built for the validation cohort, adding 
glutathione and ascorbate to the basis set as improvements 
of the previous basis set. In both cohorts, metabolites were 
quantified according to known amounts of formate and 
reported as mmoles/kg wet weight. 
In vivo magnetic resonance spectroscopy imaging
As part of a previous published study [16], 
9 patients (24 samples) in the main cohort had in vivo 
MRSI metabolic data from patients from spatially 
matched voxels to the tissue sampling sites. Due to the 
low number of samples, the samples were divided into 
two equal groups: ERGhigh for samples with ERG score 
higher than the median of the cancer samples, and ERGlow 
for the samples with ERG score lower than median. 
Three samples were excluded due to low spectral quality 
of the associated MRSI spectrum. Details regarding e.g. 
acquisition and quantification of in vivo metabolite levels 
have previously been described in Selnæs et al. [16]. 
statistical analysis
The HR-MAS MRS spectra were baseline corrected 
and peak aligned using icoshift [52] in MATLAB r2013a 
(The Mathworks, Inc., USA). Contamination signals 
from ethanol (3.65-3.69 ppm) were removed before 
normalization by probabilistic quotient normalization 
(PQN) [53]. Principal component analysis (PCA) and 
partial least squares discriminant analysis (PLS-DA) 
were performed on the Carr-Purcell-Meiboom-Gill 
(CPMG) spectra between 1.46 and 4.66 ppm. Data 
were centered prior to analysis. To avoid overfitting, 
PLS-DA models were validated through a 5-fold random 
subset cross-validation, and repeated 10 times. The 
number of latent variables was chosen based on the first 
local minima of cross-validated classification error for 
PLS- DA. Permutation testing was performed to assess the 
significance of the multivariate models (n = 1000). PCA 
and PLS-DA models were built using mixOmics in R [54] 
and PLS_toolbox 7.8.2 (Eigenvector Research, Inc., USA) 
in MATLAB, respectively. 
In the main cohort, comparisons of quantified 
metabolites and gene expression levels, including 
metabolite levels from in vivo MRSI were performed 
by using linear mixed models in Stata 13 (StataCorp, 
USA), accounting for the effect of several samples 
originating from the same patient. Gene expression 
levels for metabolic enzymes were mainly chosen 
according to their proximity and influence of the 
quantified metabolites found within KEGG pathways. 
For the polyamine pathway, genes previous reported to 
be central in polyamine metabolism, provided as the basis 
for the analyses [26]. A total of 63 genes were included 
in the study, and are listed as part of Supplementary 
Tables S5– S7. Comparisons of gene expression levels 
were performed using the most significant probe if several 
probes for the same gene were available. Adjusted linear 
mixed models were built by including the relative amount 
of stroma, benign epithelia, cancer tissue and luminal 
spaces as continuous covariates, in order to minimize 
the possible confounding effects of tissue heterogeneity. 
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Adjusted models for gene expression data are presented in 
Supplementary Tables S5–S7, while adjusted models for 
metabolic data are presented in Supplementary Tables S2, 
S8 and S9. Test for trends of metabolite levels over ERG 
groups were performed using the nptrend function in 
Stata. In the validation cohort, comparisons of metabolite 
levels between TMPRSS2-ERG positive and negative 
samples were compared using Student t-test. P-values less 
than 0.05 were considered significant and q-values less 
than 0.05 were considered significant after corrections for 
multiple testing 
Correlations between individual metabolites and 
tissue composition and relative luminal space were 
examined using Pearson’s correlation, and correlations 
are presented in Supplementary Table S19. Corrections 
for multiple testing were performed by Benjamini-
Hochberg correction. Multiple testing corrections were 
performed individually for the main- and the validation 
cohort, accounting for the number of comparisons for the 
metabolic data and the gene expression data individually. 
Prior to statistical analysis, all metabolite concentrations 
were transformed in order to obtain normal-distributed 
data or residuals. Type of transformation performed was 
based on visual inspections of resulting QQ-plots and 
histograms of the transformed data. Metabolic data were 
in general square-root transformed, except lactate which 
was log-transformed and glycine which was transformed 
by 1 divided by the square-root. 
Differences in rates of biochemical recurrence (PSA 
≥ 0.2 ng/ml) after prostatectomy were estimated with the 
Kaplan-Meier method and compared using the log rank 
statistics and the Cox proportional hazards regression 
model. Patients were classified as ERGhigh if they had one 
or more samples within ERGhigh. Patients were followed 
from date of surgery until last measured PSA or death. 
Time to event was calculated as the time in months 
between date of surgery and date of PSA-blood collection 
indicating biochemical recurrence or date of last follow-up 
blood collection. In total, 30 patients classified as ERGhigh 
or ERGlow were included in the analysis, while patients 
with only benign or ERGintermediate samples were excluded 
from the analysis.  
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